DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2931 | Klk6-in-32 | First-in-class inhibitor of Kallikrein-related peptidase 6 (KLK6), promoting the differentiation of OPCs into mature oligodendrocytes in vitro |
|
| DCC2932 | Klk6-in-42 | First-in-class inhibitor of Kallikrein-related peptidase 6 (KLK6), promoting the differentiation of OPCs into mature oligodendrocytes in vitro |
|
| DCC2933 | Kl-l9p | Novel antibiotic sensitizer, promoting the rearrangement of the bacterial membrane that enables hydrophobic antibiotics to permeate, strongly sensitizing Gram-negative bacteria to linezolid (Lzd), rifampicin (Rif), or clarithromycin (Clr) |
|
| DCC2934 | Boc-phe-leu-glup(oph) | 0 |
|
| DCC2935 | Km05382 | CDK9 inhibitor, inhibiting transcription of GAPDH |
|
| DCC2936 | km10340 | Selective S1P3 agonist |
|
| DCC2937 | Km-5-25 | Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe |
|
| DCC2938 | Km-5-66 | Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe |
|
| DCC2939 | kmi-1764 | Novel BACE1 inhibitor with a non-acidic heterocycle at the P1' position |
|
| DCC2940 | Kmn-010034 | Novel Potent Hematopoietic Prostaglandin D2 Synthase (H-PGDS) Inhibitor |
|
| DCC2941 | Kmn-80 | Novel Potent and Selective EP4 Agonist |
|
| DCC2942 | kms80013 | Novel inhibitor of amyloid- |
|
| DCC2943 | Kms88009 | Novel inhibitor of amyloid-β aggregation, ameliorating the neurodegenerative disorder |
|
| DCC2944 | Kmup-3 | Novel enhancer of cGMP activity; Aortic smooth muscle relaxant |
|
| DCC2945 | Kmup-4 | Novel enhancer of cGMP activity; Aortic smooth muscle relaxant |
|
| DCC2946 | Kongensin D | Natural anti-TNBC agent, significantly suppressing the triple-negative breast cancer (TNBC) tumor growth without causing side effects |
|
| DCC2947 | kp1212 | Novel non-chain terminating nucleoside analog anti-HIV inhibitor |
|
| DCC2948 | Kpt-6604 | Novel selective, orally bioavailable, PAK4 allosteric modulator against triple negative breast cancer |
|
| DCC2949 | Kpu-300 | Novel potent antimicrotubule agent, exhibiting potent cytotoxicity against HT-29 cells by strongly binding to tubulin and inducing microtubule depolymn. |
|
| DCC2950 | Kr-12-a4 | Potent antimicrobial peptide against gram-positive and gram-negative bacteria and relatively high LPS-neutralization activity |
|
| DCC2951 | Kr-25210 | Novel enteroviral replication inhibitor through a non-capsid binding mode with EC 50 values of 2.5, 2.2, and 3.7 μM against hRV B14, A21, and A71, respectively, targeting the replication stages in the virus |
|
| DCC2952 | Kr-31762 | Novel KATP channel opener, exerting cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury |
|
| DCC2953 | Kras(g12c)-in-1 | Novel irreversible inhibitor of KRAS(G12C) |
|
| DCC2954 | Kras4b-in-d14 | Novel specific inhibitor of oncogenic KRAS4b signaling, stabilizing the KRAS4b-PDEδ complex and remarkably decreasing tumor size and triggered apoptosis of tumor cells |
|
| DCC2955 | Kras4b-pdeδ Stabilizer C19 | Novel stabilizer of the KRAS4b-PDEδ complex, decreasing the proliferation of colorectal cancer cells, and increasing apoptosis via decreased activation of oncogenic KRAS4b signaling |
|
| DCC2956 | Krc-108 | Novel potent multi-kinase inhibitor, targeting Ron, Flt3 and TrkA as well as c-Met |
|
| DCC2957 | Krc-327 | Selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity. |
|
| DCC2958 | Krm-ii-08 | Novel potent, non-toxic, blood-brain barrier crossing, α5-GABA A R preferring ligand, enhancing a chloride-anion efflux that induces mitochondrial membrane depolarization and in response, TP53 upregulation and p53, constitutively phosphorylated at S392, c |
|
| DCC2959 | Krn4884 | Potassium channel opener |
|
| DCC2960 | Krn-8602 Hydrochloride | Topo II inhibitor, exhibiting cytotoxic effects against tumour cells |
|
